Dan Barber
PersonHeard in 2 episodes across 1 show since Sep 2025
Dan Barber is a pharmaceutical-industry executive associated with Questive Therapeutics.
Episodes
First heard
Guest appearances
Episodes per month
Public PodLume episodes featuring it, over the last year.
Show the data
| Month | Episodes |
|---|---|
| Nov 2025 | 0 |
| Dec 2025 | 0 |
| Jan 2026 | 1 |
| Feb 2026 | 0 |
| Mar 2026 | 0 |
| Apr 2026 | 0 |
| May 2026 | 0 |
| Jun 2026 | 0 |
| Jul 2026 | 0 |
| Aug 2026 | 0 |
| Sep 2026 | 0 |
| Oct 2026 | 0 |
Email alert
Email me when Dan Barber comes up on a podcast
One email a week at most, with the new episodes that mention Dan Barber. Free, no account needed, unsubscribe in one click.
What Dan Barber has said on podcasts
6 statements
EQT Therapeutics reports six FDA approvals, global sales, and 2.5 billion doses delivered.
“We've actually been around for about two decades, and over those two decades, we have six approvals with the FDA. We have product that is sold in six continents. We have 2.5 billion doses we put in the hands of patients.”
Open the episode · Mad Money w/ Jim Cramer 9/25/25Listen at 29:18
EQT’s oral anaphylaxis product could reach $1 billion worldwide at peak sales.
“with our new product, our antifilm product, we finally have a potential blockbuster product on our hands. It's under review with the FDA right now. And when I say blockbuster, in my mind, I think it could be a billion dollars worldwide at peak.”
Open the episode · Mad Money w/ Jim Cramer 9/25/25Listen at 29:39
Anafilm is the first and only oral rescue medication for anaphylaxis.
“we have the first and only oral rescue medication for the treatment of anaphylaxis.”
Open the episode · Mad Money w/ Jim Cramer 9/25/25Listen at 29:58
Statements are attributed to the speaker as said on the episode and reflect their view at the time, not PodLume's. They are not advice.
Episodes
2 episodes featuring Dan Barber, newest first